Dexamethasone Regulates EphA5, a Potential Inhibitory Factor with Osteogenic Capability of Human Bone Marrow Stromal Cells

Figure 4

Silencing of EphA5 in early-passage hBMSCs is not associated with aberrant hypermethylation of the EphA5 promoter. (a) The methylation level for the EphA5 promoter that contains two Methylation-Sensitive Restriction Enzymes (MSRE) sites was determined (). The methylation level for the EphA5 promoter in hBMSCs at P1 and P5 was much lower than that in human methylated DNA used as a positive control (PC) and similar to that in human nonmethylated DNA used as a negative control (NC). (b) EphA5 mRNA expression analysis by quantitative RT-PCR in hBMSCs treated with 5-azacytidine (5-aza-C) or 5-aza-2′-deoxycytidine (5-aza-dC) for 4 days, or valproic acid (VPA) for 24 hours (). The fold change of gene expression was normalized to the expression in mock-treated cell cultures. (c) The fold change of in the EphA5 mRNA level caused by VPA treatment at the indicated culture passage numbers was measured ().

(a)

(b)

(c)